These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24372446)

  • 1. Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura.
    Westwood JP; Langley K; Heelas E; Machin SJ; Scully M
    Br J Haematol; 2014 Mar; 164(6):858-66. PubMed ID: 24372446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement activation in thrombotic thrombocytopenic purpura.
    Réti M; Farkas P; Csuka D; Rázsó K; Schlammadinger Á; Udvardy ML; Madách K; Domján G; Bereczki C; Reusz GS; Szabó AJ; Prohászka Z
    J Thromb Haemost; 2012 May; 10(5):791-8. PubMed ID: 22372946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura.
    Tsai HM; Raoufi M; Zhou W; Guinto E; Grafos N; Ranzurmal S; Greenfield RS; Rand JH
    Thromb Haemost; 2006 May; 95(5):886-92. PubMed ID: 16676082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STEC-HUS, atypical HUS and TTP are all diseases of complement activation.
    Noris M; Mescia F; Remuzzi G
    Nat Rev Nephrol; 2012 Nov; 8(11):622-33. PubMed ID: 22986360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP.
    Cataland SR; Holers VM; Geyer S; Yang S; Wu HM
    Blood; 2014 Jun; 123(24):3733-8. PubMed ID: 24695849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura.
    Oh J; Oh D; Lee SJ; Kim JO; Kim NK; Chong SY; Huh JY; Baker RI;
    Blood Res; 2019 Sep; 54(3):218-228. PubMed ID: 31730685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of von Willebrand factor in thrombotic microangiopathy.
    Noone DG; Riedl M; Licht C
    Pediatr Nephrol; 2018 Aug; 33(8):1297-1307. PubMed ID: 28748411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombotic microangiopathies.
    Rosove MH
    Semin Arthritis Rheum; 2014 Jun; 43(6):797-805. PubMed ID: 24360024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement activation in diseases presenting with thrombotic microangiopathy.
    Meri S
    Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome.
    Scully M; Goodship T
    Br J Haematol; 2014 Mar; 164(6):759-66. PubMed ID: 24387053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies.
    Cataland SR; Wu HM
    Eur J Intern Med; 2013 Sep; 24(6):486-91. PubMed ID: 23739653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring.
    Mannucci PM; Cugno M
    Thromb Res; 2015 Nov; 136(5):851-4. PubMed ID: 26386489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and management of complement mediated thrombotic microangiopathies.
    Cataland SR; Wu HM
    Blood Rev; 2014 Mar; 28(2):67-74. PubMed ID: 24534133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade.
    Bitzan M; Hammad RM; Bonnefoy A; Al Dhaheri WS; Vézina C; Rivard GÉ
    Pediatr Nephrol; 2018 Aug; 33(8):1437-1442. PubMed ID: 29728803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
    Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
    Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: an update.
    Tsai HM
    Hematol Oncol Clin North Am; 2013 Jun; 27(3):565-84. PubMed ID: 23714312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological aspects of membranoproliferative glomerulonephritis (MPGN) and haemolytic uraemic syndrome (HUS) / thrombocytic thrombopenic purpura (TTP).
    Benz K; Amann K
    Thromb Haemost; 2009 Feb; 101(2):265-70. PubMed ID: 19190808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab.
    Pecoraro C; Ferretti AV; Rurali E; Galbusera M; Noris M; Remuzzi G
    Am J Kidney Dis; 2015 Dec; 66(6):1067-70. PubMed ID: 26409664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura.
    Noris M; Remuzzi G
    Semin Nephrol; 2010 Jul; 30(4):395-408. PubMed ID: 20807612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura.
    Ferrari S; Mudde GC; Rieger M; Veyradier A; Kremer Hovinga JA; Scheiflinger F
    J Thromb Haemost; 2009 Oct; 7(10):1703-10. PubMed ID: 19682238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.